Skip to main content

Parkinson's Disease clinical trials at UC Irvine

7 in progress, 6 open to eligible people

Showing trials for
  • A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease

    open to eligible people ages 30-80

    This is a phase 2 study designed to assess the safety, tolerability and efficacy of NLY01 in subjects with early untreated Parkinson's disease (PD). Evidence suggests NLY01, a pegylated form of exenatide, may be beneficial in PD and is being developed as a potential treatment for neurodegenerative disorders. For more information, please visit: PrismPDstudy.com

    Irvine, California and other locations

  • Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy

    open to eligible people ages 30-85

    This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the Unified Dyskinesia Rating Scale (UDysRS). Patients who complete the 12-week blinded treatment period may have the option to roll into an open-label safety extension study for an additional 12-month treatment period.

    Irvine, California and other locations

  • GDNF Gene Therapy for Parkinson's Disease

    open to eligible people ages 35-75

    The objective of this Phase 1b investigation is to evaluate the safety and potential clinical effect of AAV2-GDNF delivered to the putamen in subjects with either a recent or a long-standing diagnosis of PD.

    Irvine, California and other locations

  • Light Therapy for PD - Dose Selection

    open to eligible people ages 45 years and up

    This study aims to determine the most effective dose of light therapy to improve sleep in people with Parkinson's Disease. Four groups of participants will receive bright-white or dim-red light therapy at different times throughout the day.

    Irvine, California and other locations

  • Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease

    open to eligible people ages 50-76

    This clinical trial is designed to test whether surgically injecting nerve cells that make dopamine into the brain of Parkinson's disease patients is safe, and to monitor for potential side effects.

    Orange, California and other locations

  • Trial of Parkinson's And Zoledronic Acid

    open to eligible people ages 60 years and up

    This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 3500 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the National Institute of Aging.

    Irvine, California and other locations

  • VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)

    Sorry, in progress, not accepting new patients

    The objectives of this study are to assess the efficacy, safety and tolerability of VY-AADC02 in Patients with Parkinson's Disease with Motor Fluctuations.

    Irvine, California and other locations

Last updated: